[MALT lymphoma accompanied by elevated serum IgM levels mimicking Waldenström's macroglobulinemia]

Rinsho Ketsueki. 2018;59(12):2600-2605. doi: 10.11406/rinketsu.59.2600.
[Article in Japanese]

Abstract

A 60-year-old man with chronic hepatitis C was referred to our hospital with significantly elevated total protein and serum IgM (9,500 mg/dl) levels identified via a routine checkup. Blood examination revealed increased serum IgM-monoclonal protein and serum-soluble IL-2 receptor (sIL2R) levels. Computed tomography and fluorodeoxyglucose positron emission tomography revealed pulmonary masses, abnormal soft tissue masses surrounding the bilateral kidneys, and thickened mucous membrane of the bladder with high fluorodeoxyglucose uptake. Pathological examination of the pulmonary mass revealed infiltration of medium-sized lymphocytes and plasma cells. Immunohistochemical analysis revealed tumor cells positive for CD138 and IgM, with a low positive rate of Ki-67 expression. Notably, the tumor cell-surrounding lymphocytes were positive for CD20. Although the patient was initially regarded as having Waldenström's macroglobulinemia owing to the significantly increased serum IgM levels, based on positive IgH-MALT1 translocation and negative MYD88 L265P mutation findings, he was further diagnosed with extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). Complete remission was achieved following six cycles of rituximab + CHOP therapy. This study data suggest that analysis of the MYD88 L265P mutation in tumor cells is suitable for accurately diagnosing hematopoietic malignancies with increased IgM monoclonal protein.

Keywords: Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma); IgM monoclonal gammopathy of undetermined significance (MGUS); MYD88 L265P mutation; Waldenström's macroglobulinemia (WM).

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Diagnosis, Differential
  • Doxorubicin / therapeutic use
  • Humans
  • Immunoglobulin M / blood*
  • Lymphoma, B-Cell, Marginal Zone / blood
  • Lymphoma, B-Cell, Marginal Zone / diagnosis*
  • Male
  • Middle Aged
  • Mutation
  • Myeloid Differentiation Factor 88 / genetics
  • Prednisone / therapeutic use
  • Receptors, Interleukin-2 / blood
  • Remission Induction
  • Rituximab / therapeutic use
  • Vincristine / therapeutic use
  • Waldenstrom Macroglobulinemia

Substances

  • Immunoglobulin M
  • MYD88 protein, human
  • Myeloid Differentiation Factor 88
  • Receptors, Interleukin-2
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol